We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Optimizing Starting Material Quality for Cellular Therapeutics

Article   Aug 03, 2018 | by Dominic Clarke, PhD and Marie Aragon, RN, BSN. HemaCare Corporation

 
Optimizing Starting Material Quality for Cellular Therapeutics

Credit: Terumo BCT

 
 
 

RELATED ARTICLES

A Controversial World-first: Gene-Edited Human Babies

Article

A Chinese scientist, He Jiankui, has claimed that he helped make the world-first gene-edited babies: two twin baby girls. Reportedly, he used CRISPR-Cas9 to edit embryos for seven couples during IVF fertility treatment, and engineered the embryos to possess resistance to HIV infection. He Jiankui, from the Southern University of Science and Technology, is now facing investigation over whether the experiment was illegal.

READ MORE

Emerging Classes of Next-generation Biotherapeutics

Article

We are entering uncharted territory in biopharmaceutical development. Emerging new classes of treatments are harnessing the natural power of viruses and cells and engineering them to fight human diseases. As our arsenal of conventional therapies begins to fail, a new army of biotherapeutics is on the horizon. Here, we look at two new classes of treatments leading the charge.

READ MORE

Mitosis vs. Meiosis

Article

Mitosis and meiosis are two kinds of cell division that are essential to most forms of life on earth. Here we investigate the key differences and similarities between the two processes.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE